Autosomal dominant polycystic kidney disease and mTOR inhibitors: the narrow road between hope and disappointment.
نویسندگان
چکیده
archy of endothelial progenitor cells using human peripheral and umbilical cord blood. Blood 2004; 104: 2752–2760 8. Bahlmann FH, de Groot K, Duckert T et al. Endothelial progenitor cell proliferation and differentiation is regulated by erythropoietin. Kidney Int 2003; 64: 1648–1652 9. Bahlmann FH, de Groot K, Spandau J-M et al. Erythropoietin regulates endothelial progenitor cells. Blood 2004; 103: 921–926 10. de Groot K, Bahlmann FH, Bahlmann E et al. Kidney graft function determines endothelial progenitor cell number in renal transplant recipients. Transplantation 2005; 79: 941–945 11. Eknoyan G, Beck GJ, Cheung AK et al. Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med 2002; 347: 2010–2019 12. de Groot K, Bahlmann FH, Sowa J et al. Uremia causes endothelial progenitor cell deficiency. Kidney Int 2004; 66: 641–646 13. Krieter D, Fischer R, Merget K et al. Endothelial progenitor cells in patients on extracorporeal maintenance dialysis therapy. Nephrol Dial Transplant 2010; 25: 4023–4031 14. Carracedo J, Merino A, Nogueras S et al. On-line hemodiafiltration reduces the proinflammatory CD14CD16 monocyte-derived dendritic cells: a prospective, crossover study. J Am Soc Nephrol 2006; 17: 2315–2321 15. Swirski FK, Libby P, Aikawa E et al. Ly-6C monocytes dominate hypercholesterolemia-associated monocytosis and give rise to macrophages in atheromata. J Clin Invest 2007; 117: 195–205
منابع مشابه
Fasting in a 16-year-old girl at-risk of autosomal dominant polycystic kidney disease
Autosomal dominant polycystic kidney disease (ADPKD) is the most common form of inherited kidney disease that results in renal failure. PKD currently has no causative therapy. However, some treatment options are available, ranging from symptomatic therapy to delaying the onset of end-stage renal failure. Early diagnosis of adult polycystic kidney disease is vital in order to prevent its complic...
متن کاملRegulation of mTOR by polycystin-1: is polycystic kidney disease a case of futile repair?
Recent work has uncovered a functional link between polycystin-1 (PC1), the protein affected in autosomal-dominant polycystic kidney disease (ADPKD) and tuberin, the protein affected in tuberous sclerosis complex (TSC). These data suggest that PC1 functions by inducing the formation of a complex with tuberin and the Ser/Thr kinase mTOR thereby inhibiting mTOR activity. In normal, adult kidney, ...
متن کاملPolycystic liver disease presenting as pruritus
Polycystic liver disease (PCLD) is a rare autosomal dominant disorder which usually occurs in association with autosomal dominant polycystic kidney disease. Biliary obstruction is a rare complication of PCLD. Treatment options include percutaneous aspiration and sclerosis, surgical deroofing of cysts, liver resection or liver transplantation. Medical treatment involves the use of somatostatin a...
متن کاملThe role of the mammalian target of rapamycin (mTOR) in renal disease.
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that plays a pivotal role in mediating cell size and mass, proliferation, and survival. mTOR has also emerged as an important modulator of several forms of renal disease. mTOR is activated after acute kidney injury and contributes to renal regeneration and repair. Inhibition of mTOR with rapamycin delays recovery of renal fun...
متن کاملAbsence of mTOR Inhibitor Effect on Hepatic Cyst Growth: A Case Report of a Kidney Transplant Recipient with Autosomal Dominant Polycystic Kidney Disease
Some experimental studies have suggested a beneficial effect of the mammalian target of rapamycin (mTOR) inhibitor use on hepatic and renal cyst growth in patients with autosomal dominant polycystic kidney disease (ADPKD). However, the results of clinical studies are conflicting and the role of mTOR inhibitors is still uncertain. We report the case of a patient with ADPKD who underwent deceased...
متن کاملDefects in cell polarity underlie TSC and ADPKD-associated cystogenesis.
Clinical trials are underway for the treatment of tuberous sclerosis (TSC)-associated tumours using mTOR inhibitors. Here, we show that many of the earliest renal lesions from Tsc1+/- and Tsc2+/- mice do not exhibit mTOR activation, suggesting that pharmacological targeting of an alternative pathway may be necessary to prevent tumour formation. Patients with TSC often develop renal cysts and th...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
دوره 25 12 شماره
صفحات -
تاریخ انتشار 2010